TY - JOUR
T1 - A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine
AU - Haralambieva, Iana H.
AU - Ovsyannikova, Inna G.
AU - O'Byrne, Megan
AU - Pankratz, V. Shane
AU - Jacobson, Robert M.
AU - Poland, Gregory A.
N1 - Funding Information:
We thank the Mayo Vaccine Research Group nurses for subject recruitment and the children who participated in our studies. We thank Dr. R. Cattaneo for providing the virus used in the PRMN assay, and Robert Vierkant for his contribution to statistical analyses. We thank Nadya S. Larson for her help with the PRMN assay, and Norman Pinsky and Eric Swanson for performing the Elispot assay. This work was supported by NIH grants AI 48793 , AI 33144 and 1 UL1 RR024150-01 from the National Center for Research Resources (NCRR) , a component of the National Institutes of Health, and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
PY - 2011/6/15
Y1 - 2011/6/15
N2 - The measurement of measles-specific neutralizing antibodies, directed against the surface measles virus hemagglutinin and fusion proteins, is considered the gold standard in measles serology. We assessed functional measles-specific neutralizing antibody levels in a racially diverse cohort of 763 young healthy adolescents after receipt of two doses of measles-mumps-rubella vaccine, by the use of an automated plaque reduction microneutralization (PRMN) assay, and evaluated their relevance to protective antibody levels, as well as their associations with demographic and clinical variables. We also concurrently assessed measles-specific IFNγ Elispot responses and their relation to the observed antibody concentrations.The geometric mean titer for our cohort was 832 mIU/mL (95% CIs: 776; 891). Sixty-eight subjects (8.9%) had antibody concentrations of less than the protective threshold of 210 mIU/mL (corresponding to PRMN titer of 120; suggesting protection against symptomatic disease), and 177 subjects (23.2%) demonstrated persisting antibody concentrations above 1841 mIU/mL (corresponding to PRMN titer of 1052; suggesting total protection against viral infection), 7.4 years after vaccination, in the absence of wild-type virus boosting. The mean measles-specific IFNγ Elispot response for our cohort was 46 (95% CIs: 43; 49) IFNγ-positive spots per 200,000 cells with no relation of cellular immunity measures to the observed antibody concentrations. No significant associations between antibody titers and demographic and clinical variables, including gender and race, were observed in our study.In conclusion, in a large observational study of measles immunity, we used an automated high-throughput measles virus-specific neutralization assay to measure humoral immunity, and concurrently determined measles-specific cellular immunity to aid the assessment of potential susceptibility to measles in vaccinated populations.
AB - The measurement of measles-specific neutralizing antibodies, directed against the surface measles virus hemagglutinin and fusion proteins, is considered the gold standard in measles serology. We assessed functional measles-specific neutralizing antibody levels in a racially diverse cohort of 763 young healthy adolescents after receipt of two doses of measles-mumps-rubella vaccine, by the use of an automated plaque reduction microneutralization (PRMN) assay, and evaluated their relevance to protective antibody levels, as well as their associations with demographic and clinical variables. We also concurrently assessed measles-specific IFNγ Elispot responses and their relation to the observed antibody concentrations.The geometric mean titer for our cohort was 832 mIU/mL (95% CIs: 776; 891). Sixty-eight subjects (8.9%) had antibody concentrations of less than the protective threshold of 210 mIU/mL (corresponding to PRMN titer of 120; suggesting protection against symptomatic disease), and 177 subjects (23.2%) demonstrated persisting antibody concentrations above 1841 mIU/mL (corresponding to PRMN titer of 1052; suggesting total protection against viral infection), 7.4 years after vaccination, in the absence of wild-type virus boosting. The mean measles-specific IFNγ Elispot response for our cohort was 46 (95% CIs: 43; 49) IFNγ-positive spots per 200,000 cells with no relation of cellular immunity measures to the observed antibody concentrations. No significant associations between antibody titers and demographic and clinical variables, including gender and race, were observed in our study.In conclusion, in a large observational study of measles immunity, we used an automated high-throughput measles virus-specific neutralization assay to measure humoral immunity, and concurrently determined measles-specific cellular immunity to aid the assessment of potential susceptibility to measles in vaccinated populations.
KW - Cellular immunity
KW - Measles
KW - Neutralizing antibodies
KW - Plaque reduction microneutralization
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=79958164976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958164976&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2011.04.037
DO - 10.1016/j.vaccine.2011.04.037
M3 - Article
C2 - 21539880
AN - SCOPUS:79958164976
VL - 29
SP - 4485
EP - 4491
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 27
ER -